Biovie Inc Cash Flow Conversion Efficiency
Biovie Inc cash flow conversion efficiency. Based on the latest financial reports, Biovie Inc (BIVI) has a cash flow conversion efficiency ratio of -0.401x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.12 Million) by net assets ($10.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biovie Inc (2013–2026)
Cash flow conversion efficiency of Biovie Inc from 2013 to 2026. This chart illustrates how Biovie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIVI share price today for real-time trading data and today's change.
Biovie Inc Cash Flow Conversion Ratio Explained
Biovie Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biovie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biovie Inc ranked by their cash flow conversion efficiency. Also see how much is Biovie Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ascent Solar Technologies, Inc.
NASDAQ:ASTI
|
-0.065x |
|
Artroniq Berhad
KLSE:0038
|
0.001x |
|
Capital Point
TA:CPTP
|
-0.017x |
|
Air Industries Group
NYSE MKT:AIRI
|
0.000x |
|
RHYTHM Biosciences Ltd
AU:RHY
|
-1.037x |
|
Nordic Iron Ore
ST:NIO
|
0.002x |
|
Fat Prophets Global Property Fund
AU:FPP
|
0.016x |
|
Thai Packaging & Printing Public Company Limited
BK:TPP
|
0.007x |
Annual Cash Flow Conversion Efficiency for Biovie Inc (2013–2026)
The table below shows the annual cash flow conversion efficiency of Biovie Inc from 2013 to 2026. Review financial agility of Biovie Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $10.27 Trillion | $-19.02 Billion | -0.002x | +99.81% |
| 2025-06-30 | $19.01 Million | $-19.03 Million | -1.001x | +44.47% |
| 2024-06-30 | $15.51 Million | $-27.95 Million | -1.802x | +31.32% |
| 2023-06-30 | $15.34 Million | $-40.25 Million | -2.624x | +49.28% |
| 2022-06-30 | $3.67 Million | $-18.99 Million | -5.173x | -149.94% |
| 2021-06-30 | $5.05 Million | $-10.45 Million | -2.070x | -2832.88% |
| 2020-06-30 | $-21.50 Million | $-1.63 Million | 0.076x | +106.45% |
| 2019-06-30 | $2.13 Million | $-2.50 Million | -1.174x | +78.99% |
| 2018-06-30 | $111.20K | $-621.34K | -5.588x | -936.97% |
| 2017-06-30 | $1.16 Million | $-623.62K | -0.539x | -530.93% |
| 2016-06-30 | $1.92 Million | $-163.63K | -0.085x | -107.07% |
| 2015-06-30 | $-54.12K | $-65.38K | 1.208x | +219.80% |
| 2014-06-30 | $171.39K | $-172.83K | -1.008x | -4828.56% |
| 2013-06-30 | $490.70K | $-10.04K | -0.020x | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Be… Read more